Immunology of anti-phospholipid antibodies and cofactors

Systemic Lupus Erythematosus, Fourth Edition

Volumn , Issue , 2004, Pages 1081-1105

  Atsumi, Tatsuya ^a   Matsuura, Eiji ^b   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 8344236700     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012433901-9/50042-9     Document Type: Chapter

References (250)

1. E.N. Harris, A.E. Gharavi and G.R.V. Hughes (1985) Anti-phospholipid antibodies. Clin. Rheum. Dis. 11 591.
2. G.R.V. Hughes, E.N. Harris and A.E. Gharavi (1986) The anticardiolipin syndrome. J. Rheumatol. 13 486.
3. H.P. McNeil, C.N. Chesterman and S.A. Krilis (1991) Immunology and clinical importance of antiphospholipid antibodies. Adv. Immunol. 49 193.
4. E.N. Harris, A.E. Gharavi, M.L. Boey, B.M. Patel, C.G. Mackworth-Young, S. Loizou and G.R.V. Hughes (1983) Anti-cardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2 1211.
5. A. Wassermann, A. Neisser and C. Bruck (1906) Eine serodiagnostishe reaction bei syphilis. Dtsch. Med. Wochenschr. 32 745.
6. M.C. Pangborn (1941) A new serologically active phospholipid from beef heart. Proc. Soc. Exp. Biol. Med. 48 745.
7. M.C. Pangborn (1942) Isolation and purification of a serologically active phospholipid from beef heart. J. Biol. Chem. 143 247.
8. J.E. Moore and W.B. Lutz (1955) The natural history of systemic lupus erythematosus: An approach to its study through chronic biological false positive reactors. J. Chronic Dis. 1 297.
9. J.E. Moore and C.F. Mohr (1952) Biologically false positive serologic test for syphilis. JAMA 150 467.
10. J.F. Mueller, O. Ratnoff and R.W. Henile (1951) Observations on the characteristics of an unusal circulating anticoagulant. J. Lab. Clin. Med. 38 254.
11. A.B. Laurell and I.M. Nilsson (1957) Hypergamma-globulinaemia, circulating anticoagulant, and biological false positive Wassermann reaction: A study of two cases. J. Lab. Clin. Med. 49 694.
12. J.R. Haserick and R. Long (1951) Systemic lupus erythematosus preceded by false positive fest for syphilis: Presentation of five cases. Ann. Intern. Med. 37 559.
13. A.M. Harvey and L.E. Shulman (1966) Connective tissue disease and the chronic biologic false-positive test for syphilis (BFP reaction). Med. Clin. North Am. 50 1271.
14. C.L. Conley and R.C. Hartmann (1952) A hemorrhogic disorder caused by circulating anticoagulants in patients with disseminated lupus erythematosus. J. Lab. Clin. Med. 31 621.
15. D.I. Feinstein and S.I. Rapaport (1972) Acquired inhibitors of blood coagulation. Prog. Hemost. Thromb. 1 75.
16. E.J.W. Bowie, J.H. Thompson and C.A. Pascuzzi (1963) Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J. Lab. Clin. Med. 62 416.
17. T. Koike, M. Sueishi, H. Funaki, H. Tomioka and S. Yoshida (1984) Antiphospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 56 193.
18. H.P. McNeil, R.J. Simpson, C.N. Chesterman and S.A. Krilis (1990) Anti-phospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. U.S.A. 87 4120.
19. M. Galli, P. Comfurius, C. Maassen, H.C. Hemker, M.H. de Baets, P.J.C. van Breda-Vriesman, T. Barbui, R.F.A.Z. Zwaal and E.M. Bevers (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335 952.
20. E. Matsuura, Y. Igarashi, M. Fujimoto, K. Ichikawa and T. Koike (1990) Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336 177.
21. E. Matsuura, Y. Igarashi, T. Yasuda, D.A. Triplett and T. Koike (1994) Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179 457.
22. E.M. Bevers, M. Galli, T. Barbui, P. Comfurius and R.F. Zwaal (1991) Lupus anticoagulant IgG's (LA) are not directed to phospholipids only but to a complex of lipid-bound human prothrombin. Thromb. Haemost. 66 629.
23. J. Matsuda, N. Saitoh, K. Gohchi, M. Gotoh and M. Tsukamoto (1994) Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am. J. Hematol. 47 56.
24. J.D. Oosting, R.H.W.M. Derksen, I.W.G. Bobbink, T.M. Hackeng, B.N. Bouma and P.G. de Groot (1993) Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism? Blood 81 2618.
25. T. Sugi and J.A. McIntyre (1995) Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 86 3083.
26. W.A. Wilson, A.E. Gharavi, T. Koike, M.D. Lockshin, D.W. Branch, J.C. Piette, R. Brey, R. Derksen, E.N. Harris, G.R. Hughes, D.A. Triplett and M.A. Khamashta (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42 1309.
27. L. Stryer (1988) Introduction to biological membranes. Biochemistry 3rd ed New York: Freeman
28. J.A.F. Op dem Kamp (1979) Lipids asymmetry in membranes. Annu. Rev. Biochem. 48 47.
29. T. Koike, A. Tsutsumi, K. Ichikawa and E. Matsuura (1995) Antigenic specificity of the “anticardiolipin” antibodies. Blood 85 2277.
30. M. Igarashi, E. Matsuura, Y. Igarashi, H. Nagae, K. Ichikawa, D.A. Triplett and T. Koike (1996) Human β2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a Baculovirus system. Blood 87 3262.
31. R.A.S. Roubey, R.A. Eisenberg, M.F. Harper and J.B. Winfield (1995) “Anticardiolipin” autoantibodies recognize β2-glycoprotein I in the absence of phospholipid. J. Immunol. 154 954.
32. A. Tincani, L. Spatola, E. Prati, F. Allegri, P. Ferremi, R. Cattaneo, P. Meroni and G. Balestrieri (1996) The anti-β2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native β2-glycoprotein I and preserved during species' evolution. J. Immunol. 157 5732.
33. T. Koike and E. Matsuura (1991) What is the “true” antigen for anticardiolipin antibodies? Lancet 337 671.
34. E. Matsuura, Y. Igarashi, M. Fujimoto, K. Ichikawa, T. Suzuki, S. Yoshida and T. Koike (1992) Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J. Immunol. 148 3885.
35. J. Hunt and S. Krilis (1994) The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys281–Cys288) and a region recognized by anticardiolipin antibodies. J. Immunol. 152 653.
36. A. Tsutsumi, K. Ichikawa, E. Matsuura, K. Sawada and T. Koike (2000) Heterogeneous behavior of anti-β2-glycoprotein I antibodies on various commercially available enzyme immunoassay plates coated with β2-glycoprotein I. J. Rheumatol. 27 391.
37. L.W. Chamley, A.M. Duncalf, B. Konarkowska, M.D. Mitchell and P.M. Johnson (1999) Conformationally altered β2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies. Clin. Exp. Immunol. 115 571.
38. M. Galazka, M. Tang, V.A. DeBari, J.D. Kohles, J.K. Lee, L.B. Keil and M. Petersheim (1999) Modification of β2-glycoprotein I by glutardialdehyde. Conformational changes and aggregation accompany exposure of the cryptic autoepitope. Appl. Biochem. Biotechnol. 76 1.
39. Y. Sheng, D.A. Kandiah and S.A. Krilis (1998) Anti-β2-glycoprotein I autoantibodies from patients with the “antiphospholipid” syndrome bind to β2-glycoprotein I with low affinity: Dimerization of β2-glycoprotein I induces a significant increase in anti-β2-glycoprotein I antibody affinity. J. Immunol. 161 2038.
40. J. George, B. Gilburd, M. Hojnik, Y. Levy, P. Langevitz, E. Matsuura, T. Koike and Y. Shoenfeld (1998) Target recognition of β2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: Evidence for involvement of the fourth domain of β2GPI in antibody binding. J. Immunol. 150 3917.
41. G.M. Iverson, E.J. Victoria and D.M. Marquis (1998) Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI. Proc. Natl. Acad. Sci. U.S.A. 95 15542.
42. P.A. NcNeeley, J.S. Dlott, R.A. Furie, R.M. Jack, T.L. Ortel, D.A. Triplett, E.J. Victoria and M.D. Linnik (2001) β2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I. Thromb. Haemost. 86 590.
43. T. Koike, K. Ichikawa, T. Atsumi, H. Kasahara and E. Matsuura (2000) β2-glycoprotein I-anti-β2-glycoprotein I interaction. J. Autoimmun. 15 97.
44. H.E. Schultze, K. Heide and H. Haput (1961) Uber ein bisher ubekanntes niedermolekulars β2-Globulin des Humanserums. Naturwissenschaften 48 719.
45. H. Wurm (1984) β2-glycoprotein (apolipoprotein H) interactions with phospholipid vesicles. Int. J. Biochem. 16 511.
46. E. Polz (1979) H. Peeters (Eds) Isolation of a specific lipid-binding protein from human serum by affinity chromatography using heparin Sepharose Oxford: Pergamon
47. E. Polz and G.M. Kostner (1979) The binding of β2-glycoprotein-I to human serum lipoproteins: Distribution among density fractions. FEBS Lett. 102 183.
48. J. Nimpf, E.M. Bevers, P.H. Bomans, U. Till, H. Wurm, G.M. Kostner and R.F. Zwaal (1986) Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim. Biophys. Acta 884 142.
49. I. Schousboe (1985) β2-glycoprotein I: Plasma inhibitor of contact activation of the intrinsic blood coagulation pathway. Blood 66 1086.
50. J. Nimpf, H. Wurm and G.M. Kostner (1987) β2-glycoprotein-I (apo-H) inhibits the release reaction of human plateletsduring ADP-induced aggregation. Atherosclerosis 63 109.
51. J. Lozier, N. Takahashi and F.W. Putnam (1984) Complete amino acid sequence of human plasma β2-glycoprotein I. Proc. Natl. Acad. Sci. U.S.A. 81 3640.
52. H. Kato and K. Enjyoji (1991) Amino acid sequence and location of the disulfide bonds in bovine β2-glycoprotein I: The presence of five Sushi domains. Biochemistry 30 11687.
53. E. Matsuura, M. Igarashi, Y. Igarashi, H. Nagae, K. Ichikawa, T. Yasuda and T. Koike (1991) Molecular definition of human β2-glycoprotein I (β2-GPI) by cDNA cloning and inter species differences of β2-GPI in alternation anticardiolipin binding. Int. Immunol. 3 1217.
54. A. Steinkasserer, C. Estaller, E.H. Weiss, R.B. Sim and A.J. Day (1991) Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. Biochem. J. 277 387.
55. K.B. Reid and A.J. Day (1989) Structure-function relationships of the complement components. Immunol. Today 10 177.
56. B. Bouma, P.G. de Groot, J.M. van den Elsen, R.B. Ravelli, A. Schouten, M.J. Simmelink, R.H. Derksen, J. Kroon and P. Gros (1999) A dhesion mechanism of human β(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 18 5166.
57. R. Schwarzenbacher, K. Zeth, K. Diederichs, A. Gries, G.M. Kostner, P. Laggner and R. Prassl (1999) Crystal structure of human beta2-glycoprotein I: Implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 18 6228.
58. A. Steinkasserer, P.N. Barlow, A.C. Willis, Z. Kertesz, I.D. Campbell, R.B. Sim and D.G. Norman (1992) Activity, disulphide mapping and structural modelling of the fifth domain of human β2-glycoprotein I. FEBS Lett. 313 193.
59. E. Matsuura, M. Igarashi, Y. Igarashi, T. Katahira, H. Nagae, K. Ichikawa, D.A. Triplett and T. Koike (1995) Molecular studies on phospholipid-binding sites and cryptic epitopes appering on β2-glycoprotein I structure recognized by anticardiolipin antibodies. Lupus 4(Suppl. 1), S13.
60. Y. Sheng, A. Sali, H. Herzog, J. Lahnstein and S.A. Krilis (1996) Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J. Immunol. 157 3744.
61. J.E. Hunt, R.J. Simpson and S.A. Krilis (1993) Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc. Natl. Acad. Sci. U.S.A. 90 2141.
62. M. Hoshino, Y. Hagihara, I. Nishii, T. Yamazaki, H. Kato and Y. Goto (2000) Identification of the phospholipid-binding site of human β2-glycoprotein I domain V by heteronuclear magnetic resonance. J. Mol. Biol. 304 927.
63. D.P. Hong, Y. Hagihara, H. Kato and Y. Goto (2001) Flexible loop of β2-glycoprotein I domain V specifically interacts with hydrophobic ligands. Biochemistry 40 8092.
64. A.T. Lee, K. Balasubramanian and A.J. Schroit (2000) β2-glycoprotein I-dependent alterations in membranne properties. Biochim. Biophys. Acta 1509 475.
65. Y. Hagihara, K. Enjyoji, T. Omasa, Y. Katakura, K. Suga, M. Igarashi, E. Matsuura, H. Kato, T. Yoshimura and Y. Goto (1997) Structure and function of the recombinant fifth domain of human β2-glycoprotein I: Effects of specific cleavage between Lys77 and Thr78. J. Biochem. (Tokyo) 121 128.
66. N. Ohkura, Y. Hagihara, T. Yoshimura, Y. Goto and H. Kato (1998) Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form. Blood 91 4173.
67. E. Matsuura, J. Inagaki, H. Kasahara, D. Yamamoto, T. Atsumi, K. Kobayashi, K. Kaihara, D. Zhao, K. Ichikawa, A. Tsutsumi, T. Yasuda, D.A. Triplett and T. Koike (2000) Proteolytic cleavage of β2-glycoprotein I: Reduction of antigenicity and the structural relationship. Int. Immunol. 12 1183.
68. T.A. Brighton, P.J. Hogg, Y.P. Dai, B.H. Murray, B.H. Chong and C.N. Chesterman (1996) Beta2-glycoprotein I in thrombosis: Evidence for a role as a natural anticoagulant. Br. J. Haematol. 93 185.
69. D.A. Horbach, E. van Oort, T. Lisman, J.C. Meijers, R.H. Derksen and P.G. de Groot (1999) β2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb. Haemost. 81 87.
70. Y. Itoh, K. Inuzuka, I. Kohno, H. Wada, H. Shiku, N. Ohkura and H. Kato (2000) Highly increased plasma concentrations of the nicked form of β2 glycoprotein I in patients with leukemia and with lupus anticoagulant: Measurement with a monoclonal antibody specific for a nicked form of domain V. J. Biochem. (Tokyo) 128 1017.
71. A. Steinkasserer, D.J. Cockburn, D.M. Black, Y. Boyd, E. Solomon and R.B. Sim (1992) Assignment of apolipoprotein H (APOH: β-2-glycoprotein I) to human chromosome 17q23-qter; determination of the major expression site. Cytogenet. Cell Genet. 60 31.
72. L.W. Chamley, J.L. Allen and P.M. Johnson (1997) Synthesis of β2 glycoprotein 1 by the human placenta. Placenta 18 403.
73. B. Caronti, C. Calderaro, C. Alessandri, F. Conti, R. Tinghino, G. Palladini and G. Valesini (1999) β2-glycoprotein I (β2-GPI) mRNA is expressed by several cells types involved in anti-phospholipid syndrome-related tissue damage. Clin. Exp. Immunol. 115 214.
74. L.W. Chamley, N.S. Pattison and E.J. McKay (1993) Elution of anticardiolipin antibodies and their cofactor β2-glycoprotein 1 from the placentae of patients with a poor obstetric history. J. Reprod. Immunol. 25 209.
75. M.I. Kamboh, R.E. Ferrell and B. Sepehrnia (1988) Genetic studies of human apolipoprotein. IV. Structural heterogeneity of apolipoprotein H (β2-glycoprotein I). Am. J. Hum. Genet. 42 452.
76. M.I. Kamboh and R.E. Ferrell (1991) Apolipoprotein H polymorphism and its role in lipid metabolism. Adv. Lipid Res. 1 9.
77. H. Mehdi, C.E. Aston, D.K. Sanghera, R.F. Hamman and M.I. Kamboh (1999) Genetic variation in the apolipoprotein H (β2-glycoprotein I) gene affects plasma apolipoprotein H concentrations. Hum. Genet. 105 63.
78. D.K. Sanghera, T. Kristensen, R.F. Hamman and M.I. Kamboh (1997) Molecular basis of the apolipoprotein H (β2-glycoprotein I) protein polymorphism. Hum. Genet. 100 57.
79. F.C. Gushiken, F.C. Arnett, C. Ahn and P. Thiagarajan (1999) Polymorphism of beta2-glycoprotein I at codons 306 and 316 in patients with systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 42 1189.
80. N. Hirose, R. Williams, A.R. Alberts, R.A. Furie, E.K. Chartash, R.I. Jain, C. Sison, R.G. Lahita, J.T. Merrill, E. Cucurull, A.E. Gharavi, L.R. Sammaritano, J.E. Salmon, S. Hashimoto, T. Sawada, C.C. Chu, P.K. Gregersen and N. Chiorazzi (1999) A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum. 42 1655.
81. T. Atsumi, A. Tsutsumi, O. Amengual, M.A. Khamashta, G.R. Hughes, Y. Miyoshi, K. Ichikawa and T. Koike (1999) Correlation between beta2-glycoprotein I valine/leucine247 polymorphism and anti-beta2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome. Rheumatology 38 721.
82. S. Yasuda, A. Tustsumi, H. Chiba, H. Yanai, Y. Miyoshi, R. Takeuchi, T. Horita, T. Atsumi, K. Ichikawa, E. Matsuura and T. Koike (2000) Beta(2)-glycoprotein I deficiency: Prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 152 337.
83. S.K. Moestrup, I. Schousboe, C. Jacobsen, J.R. Leheste, E.I. Christensen and T.E. Willnow (1998) β2-glycoprotein-I (apolipoprotein H) and β2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin. J. Clin. Invest. 102 902.
84. J.H. Berden, L. Hang, P.J. McConahey and F.J. Dixon (1983) Analysis of vascular lesions in murine SLE. I. Association with serologic abnormalities. J. Immunol. 130 1699.
85. L.M. Hang, S. Izui and F.J. Dixon (1981) (NZW × BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J. Exp. Med. 154 216.
86. L. Hang, P. Stephens-Larson, J.P. Henry and F.J. Dixon (1983) The role of hypertension in the vascular disease and myocardial infarcts associated with murine systemic lupus erythematosus. Arthritis Rheum. 26 1340.
87. H. Yoshida, H. Fujiwara, T. Fujiwara, S. Ikehara and Y. Hamashima (1987) Quantitative analysis of myocardial infarction in (NZW × BXSB)F1 hybrid mice with systemic lupus erythematosus and small coronary artery disease. Am. J. Pathol. 129 477.
88. Y. Hashimoto, M. Kawamura, K. Ichikawa, T. Suzuki, T. Sumida, S. Yoshida, E. Matsuura, S. Ikehara and T. Koike (1992) Anticardiolipin antibodies in NZW × BXSB F1 mice. A model of antiphospholipid syndrome. J. Immunol. 149 1063.
89. M. Blank, D. Faden, A. Tineani, J. Kopolovic, I. Goldberg, B. Gilburd, F. Allegri, G. Balestrieri, G. Valesini and Y. Shoenfeld (1994) Immunization with anticardiolipin cofactor (β-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J. Autoimmun. 7 441.
90. S. Kouts, M.X. Wang, S. Adelstein and S.A. Krilis (1995) Immunization of a rabbit with β2-glycoprotein I induces charge-dependent crossreactive antibodies that bind anionic phospholipid and have similar reactivity as autoimmune anti-phospholipid antibodies. J. Immunol. 155 958.
91. J. George, M. Blank, B. Gilburd, M. Hojnik, B. Shenkman, I. Tamarin, D. Varon, E. Matsuura, T. Koike and Y. Shoenfeld (1997) Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human β2-glycoprotein I. Int. Immunol. 9 913.
92. S.S. Pierangeli, X.W. Liu, G. Anderson, J.H. Barker and E.N. Harris (1996) Thrombogenic properties of murine anti-cardiolipin antibodies induced by β2 glycoprotein I and human immunoglobulin G antiphospholipid antibodies. Circulation 94 1746.
93. Y. Sheng, S.W. Reddel, H. Herzog, Y.X. Wang, T. Brighton, M.P. France, S.A. Robertson and S.A. Krilis (2001) Impaired thrombin generation in β2-glycoprotein I null mice. J. Biol. Chem. 276 13817.
94. K. Ichikawa, M. Khamashta, T. Koike, E. Matsuura and G.R.V. Hughes (1994) Reactivity of monoclonal anti-cardiolipin antibodies from patients with the antiphospholipid syndrome to β2-glycoprotein I. Arthritis Rheum. 37 1453.
95. M. Igarashi, E. Matsuura, Y. Igarashi, H. Nagae, Y. Matsuura, K. Ichikawa, T. Yasuda, D.R. Voelker and T. Koike (1993) Expression of anticardiolipin cofactor, human β2-glycoprotein I, by a recombinant baculovirus/insect cell system. Clin. Exp. Immunol. 93 19.
96. K. Ichikawa, A. Tsutsumi, T. Atsumi, E. Matsuura, S. Kobayashi, G.R.V. Hughes, M.A. Khamashta and T. Koike (1999) A chimeric antibody with the human gammal constant region as a putative standard for assays to detect IgG β2-glycoprotein I-dependent anticardiolipin and anti-β2-glycoprotein I antibodies. Arthritis Rheum. 42 2461.
97. N. Hattori, M. Kuwana, J. Kaburaki, T. Mimori, Y. Ikeda and Y. Kawakami (2000) T cells that are autoreactive to β2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum. 43 65.
98. T. Arai, K. Yoshida, J. Kaburaki, H. Inoko, Y. Ikeda, Y. Kawakami and M. Kuwama (2001) Autoreactive CD4(+) T-cell clones to β2-glycoprotein I in patients with antiphospholipid syndrome: Preferential recognition of the major phospholipid-binding site. Blood 98 1889.
99. J.E. Hunt, H.P. McNeil, G.J. Morgan, R.M. Crameri and S.A. Krilis (1992) A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1 75.
100. A. Tsutsumi, E. Matsuura, K. Ichikawa, A. Fujisaku, M. Mukai, S. Kobayashi and T. Koike (1996) Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis. Rheum. 39 1466.
101. D.A. Triplett and J.T. Brandt (1988) Lupus anticoagulants: Misnomer, paradox, riddle, epiphenomenon. Hematol. Pathol. 2 121.
102. D.A. Triplett (1994) Assays for detection of antiphospholipid antibodies. Lupus 3 281.
103. M.H. Rosove and P.M. Brewer (1992) Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann. Intern. Med. 117 303.
104. P. Thiagarajan, S.S. Shapiro and L. De Marco (1980) Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J. Clin. Invest. 66 397.
105. M. Galli, S. Beguin, T. Lindhout and C.H. Hemker (1989) Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulants. Br. J. Haematol. 72 549.
106. E.T. Yin and G.L. W (1965) Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb. Haemost. 14 88.
107. T. Exner, K.A. Rickard and H. Kronenberg (1978) A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br. J. Haematol. 40 143.
108. J.D. Oosting, R.H.W.M. Derksen, H.T. Entjes, B.N. Bouma and P.G. de Groot (1992) Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb. Haemost. 67 499.
109. R.A.S. Roubey, C.W. Pratt, J.P. Buyon and J.B. Winfield (1992) Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2-glycoprotein I. J. Clin. Invest. 90 1100.
110. H. Takeya, T. Mori, E.C. Gabazza, K. Kuroda, H. Deguchi, E. Matsuura, K. Ichikawa, T. Koike and K. Suzuki (1997) Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. J. Clin. Invest. 99 2260.
111. J. Arnout and J. Vermylen (1998) Mechanism of action of β2-glycoprotein I-dependent lupus anticoagulants. Lupus 7(Suppl. 1), 23.
112. J. Arnout, M. Vanrusselt, C. Wittevrongel and J. Vermylen (1998) Monoclonal antibodies against beta-2-glycoprotein I: Use as reference material for lupus anticoagulant tests. Thromb. Haemost. 79 955.
113. M.F. Harper, P.M. Hayes, B.R. Lentz and R.A.S. Roubey (1998) Characterization of β2-glycoprotein I binding to phospholipid membranes. Thromb. Haemost. 80 610.
114. G.M. Willems, M.P. Janssen, M.M. Pelsers, P. Comfurius, M. Galli, R.F. Zwaal and E.M. Bevers (1996) Role of divalency in the high-affinity binding of anticardiolipin antibody-β2-glycoprotein I complexes to lipid membranes. Biochemistry 35 13833.
115. J. Arnout, C. Wittevrongel, M. Vanrusselt, M. Hoylaerts and J. Vermylen (1998) β-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody β-2-glycoprotein I complexes on phospholipid surfaces. Thromb. Haemost. 79 79.
116. L.V.M. Rao, A.D. Hoang and S.I. Rapaport (1995) Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin. Thromb. Haemost. 73 668.
117. S.S. Pierangeli, G.H. Goldsmith, D.W. Branch and E.N. Harris (1997) Antiphospholipid antibody: Functional specificity for inhibition of prothrombin activation by the prothrombinase complex. Br. J. Haematol. 97 768.
118. M.J. Simmelink, D.A. Horbach, R.H. Derksen, J.C. Meijers, E.M. Bevers, G.M. Willems and P.G. de Groot (2001) Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br. J. Haematol. 113 621.
119. L.V. Rao, A.D. Hoang and S.I. Rapaport (1996) Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 88 4173.
120. M. Galli, L. Ruggeri and T. Barbui (1998) Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 91 1999.
121. D.A. Triplett (1998) Many faces of lupus anticoagulants. Lupus 7(Suppl. 2), S18.
122. J.T. Brandt, D.A. Triplett, B. Alving and I. Scharrer (1995) Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb. Haemost. 74 1185.
123. D.A. Triplett (2000) Use of the dilute Russell viper venom time (dRVVT): Its importance and pitfalls. J. Autoimmun. 15 173.
124. D.A. Triplett, J.T. Brandt, D. Kaczor and J. Schaeffer (1983) Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am. J. Clin. Pathol. 79 678.
125. B. Lesperance, M. David, J. Rauch, C. Infante-Rivard and G.E. Rivard (1988) Relative sensitivity of different tests in the detection of low titer lupus anticoagulants. Thromb. Haemost. 60 217.
126. R.R. Forastiero, C.R. Falcon and L.O. Carreras (1990) Comparison of various screening and confirmatory tests for the detection of the lupus anticoagulant. Haemostasis 20 208.
127. V. Pengo, A. Biasiolo, P. Rampazzo and T. Brocco (1999) dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-β2-glycoprotein I autoantibodies. Throm b. Haemost. 81 256.
128. T. Exner (2000) Conceptions and misconceptions in testing for lupus anticoagulants. J. Autoimmun. 15 179.
129. J. Arnout, P. Meijer and J. Vermylen (1999) Lupus anticoagulant testing in Europe: An analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb. Haemost. 81 929.
130. M. Galli, G. Finazzi, E.M. Bevers and T. Barbui (1995) Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and β2-glycoprotein I-dependent antiphospholipid antibodies. Blood 86 617.
131. I.J. Mackie, S. Donohoe and S.I. Machin (2000) Lupus anticoagulant measurement. M.A. Khamashta (Eds) Hughes Syndrome London: Springer-Verlag
132. S.P. Bajaj, S.I. Rapaport, D.S. Fierer, K.D. Herbst and D.B. Schwartz (1983) A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 61 684.
133. J.R. Edson, J.M. Vogt and D.K. Hasegawa (1984) Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 64 807.
134. R.A. Fleck, S.I. Rapaport and L.V.M. Rao (1988) Anti-prothrombin antibodies and the lupus anticoagulant. Blood 72 512.
135. S.P. Bajaj, S.I. Rapaport, S. Barclay and K.D. Herbst (1985) Acquired hypoprothrombinemia due to nonneutralizing antibodies to prothrombin: Mechanism and management. Blood 65 1538.
136. M. Galli, E.M. Bevers, P. Comfurius, T. Barbui and R.F. Zwaal (1993) Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br. J. Haematol. 83 466.
137. J. Arvieux, L. Darnige, C. Caron, G. Reber, J.C. Bensa and M.G. Colomb (1995) Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulant. Thromb. Haemost. 74 1120.
138. M. Galli, G. Beretta, M. Daldossi, E.M. Bevers and T. Barbui (1997) Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb. Haemost. 77 486.
139. R.G. Malia, C. Brooksfield, I. Bulman and M. Greaves (1997) Prothrombin fragment F1–2: The epitope for antiphospholipid antibody expression. Thromb. Haemost. 171(Suppl.), 689.
140. M. Puurunen, O. Vaarala, H. Julkunen, K. Aho and T. Palosuo (1996) Antibodies to phospholipid-binding plasma proteins and occurence of thrombosis in patients with systemic lupus erythematosus. Clin. Immunol. Immunopathol. 80 16.
141. M.L. Bertolaccini, T. Atsumi, M.A. Khamashta, O. Amengual and G.R.V. Hughes (1998) Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J. Rheumatol. 25 1104.
142. M. Sorice, V. Pittoni, A. Circella, R. Misasi, F. Conti, A. Longo, G.M. Pontieri and G. Valesini (1998) Antiprothrombin but not “pure” anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome. Thromb. Haemost. 80 713.
143. O. Vaarala, M. Puurunen, M. Manttari, V. Manninen, K. Aho and T. Palosuo (1996) Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb. Haemost. 75 456.
144. T. Palosuo, J. Virtamo, J. Haukka, P.R. Taylor, K. Aho, M. Puurunen and O. Vaarala (1997) High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men—a nested case-control study. Thromb. Haemost. 78 1178.
145. V. Pengo, A. Biasiolo, T. Brocco, S. Tonetto and A. Ruffatti (1996) Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb. Haemost. 75 721.
146. D.A. Horbach, E. van Oort, R.C. Donders, R.H. Derksen and P.G. de Groot (1996) Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb. Haemost. 76 916.
147. R.R. Forastiero, M.E. Martinuzzo, G.S. Cerrato, L.C. Kordich and L.O. Carreras (1997) Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb. Haemost. 78 1008.
148. J. Swadzba, L.S. de Clerck, W.J. Stevens, C.H. Bridts, K.A. van Cotthem, J. Musial, M. Jankowski and A. Szczeklik (1997) Anticardiolipin, anti-β2-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J. Rheumatol. 24 1710.
149. J. Guerin, O. Smith, B. White, G. Sweetman, C. Feighery and J. Jackson (1998) Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders. Br. J. Haematol. 102 896.
150. T. Atsumi, M. Ieko, M.L. Bertolaccini, K. Ichikawa, A. Tsutsumi, E. Matsuura and T. Koike (2000) Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 43 1982.
151. R. Huber, R. Berendes and A. Burger (1994) Annexin V: Crystal structure and its implications on function. S.E. Moss (Eds) The Annexins London: Portland Press
152. H.A.M. Andree, W.T. Hermens and H.C. Hemker (1992) Displacement of factor Va by annexin V. H.A.M. Andree (Eds) Phospholipid Binding and Anticoagulant Action of Annexin V Maastricht: Universitaire Pers Maastricht
153. G. Krikun, C.J. Lockwood, X.X. Wu, X.D. Zhou, S. Guller, C. Calandri, A. Guha, Y. Nemerson and J.H. Rand (1994) The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: Immunolocalization and in vitro regulation. Placenta 15 601.
154. J.H. Rand, X.X. Wu, S. Guller, J. Gil, A. Guha, J. Scher and C.J. Lockwood (1994) Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am. J. Obstet. Gynecol. 171 1566.
155. J.C. Gris, I. Quere, M. Sanmarco, B. Boutiere, E. Mercier, J. Amiral, A.M. Hubert, S. Ripart-Neveu, M. Hoffet, M.L. Tailland, O. Rousseau, F. Monpeyroux, M. Dauzat, J. Sampol, J.P. Daures, J. Berlan and P. Mares (2000) Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study-NOHA. Thromb. Haemost. 84 228.
156. G. Lakos, E. Kiss, N. Regeczy, P. Tarjan, P. Soltesz, M. Zeher, E. Bodolay, G. Szucs, S. Szakony, S. Sipka and G. Szegedi (2000) Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. J. Rheumatol. 27 924.
157. N. Nakamura, T. Ban, K. Yamaji, Y. Yoneda and Y. Wada (1998) Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. J. Clin. Invest. 101 1951.
158. N. Nakamura, C. Kuragaki, Y. Shidara, K. Yamaji and Y. Wada (1995) Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties. Am. J. Haematol. 49 347.
159. J.H. Rand, X.X. Wu, H.A. Andree, C.J. Lockwood, S. Guller, J. Scher and P.C. Harpel (1997) Pregnancy loss in the antiphospholipid-antibody syndrome—a possible thrombogenic mechanism. N. Engl. J. Med. 337 154.
160. J.H. Rand, X.X. Wu, H.A. Andree, J.B. Ross, E. Rusinova, M.G. Gascon-Lema, C. Calandri and P.C. Harpel (1998) Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A “lupus procoagulant” phenomenon. Blood 92 1652.
161. M.D. Smirnov and C.T. Esmon (1994) Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J. Biol. Chem. 269 816.
162. C.E. Weidmann, D.J. Wallace, J.B. Peter, P.J. Knight, M.B. Bear and J.R. Klinenberg (1988) Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J. Rheumatol. 15 74.
163. H.L. Staub, E.N. Harris and M.A. Khamashta (1989) Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann. Rheum. Dis. 48 166.
164. C.R. Falcon, A.M. Hoffer and L.O. Carreras (1990) Evaluation of the clinical and laboratory associations of antiphosphatidylethanolamine antibodies. Thromb. Res. 59 383.
165. M.L. Bertolaccini, B. Roch, O. Amengual, T. Atsumi, M.A. Khamashta and G.R.V. Hughes (1998) Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br. J. Rheumatol. 37 1229.
166. T. Sugi and J.A. McLntyre (1996) Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb. Haemost. 76 354.
167. J.A. McIntyre and D.R. Wagenknecht (2000) Antiphosphatidylethanolamine (aPE) antibodies: A survey. J. Autoimmun. 15 185.
168. P. Reverdiau-Moalic, B. Delahousse, G. Body, P. Bardos, J. Leroy and Y. Gruel (1996) Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood. 88 900.
169. M. Berard, R. Chantome, A. Marcelli and M.C. Boffa (1996) Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J. Rheumatol. 23 1369.
170. M.C. Boffa, M. Berard, T. Sugi and J.A. McIntyre (1996) Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity. J. Rheumatol. 23 1375.
171. T. Sugi, J. Katsunuma, S. Izumi, J.A. McIntyre and T. Makino (1999) Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil. Steril. 71 1060.
172. D.W. Jones, M.J. Gallimore, S.L. Harris and M. Winter (1999) Antibodies to factor XII associated with lupus anticoagulant. Thromb. Haemost. 81 387.
173. W. Shi, B. Chong, P. Hogg and C. Chesterman (1993) Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb. Haemost. 70 342.
174. S. Nomura, S. Fukuhara, Y. Komiyama, H. Takahashi, E. Matsuura, T. Nakagaki, A. Funatsu, T. Sugo, M. Matsuda and T. Koike (1994) β2-Glycoprotein I and anticardiolipin antibody influence factor Xa generation but not factor Xa binding to platelet-derived microparticles. Thromb. Haemost. 71 526.
175. C.T. Esmon and W.G. Owen (1981) Identification of an endothelial cell cofactor for thrombin-catalysed activation of protein C. Proc. Natl. Acad. Sci. U.S.A. 78 2249.
176. N.L. Esmon, W.G. Owen and C.T. Esmon (1982) Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J. Biol. Chem. 257 859.
177. J. Ye, N.L. Esmon, C.T. Esmon and A.E. Johnson (1991) The active site of thrombin is altered upon binding to thrombomodulin. Two distinct structural changes are detected by fluorescence, but only one correlates with protein C activation. J. Biol. Chem. 266 23016.
178. K. Suzuki, J. Stenflo, B. Dahlbäck and B. Teodorsson (1983) Inactivation of human coagulation Factor V by activated protein C. J. Biol. Chem. 258 1914.
179. B. Dahlback (1991) Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb. Haemost. 66 49.
180. P.G. de Groot and R.H.W.M. Derksen (1994) Protein C pathway, antiphospholipid antibodies and thrombosis. Lupus 3 229.
181. R. Cariou, G. Tobelem, C. Soria and J. Caen (1986) Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N. Engl. J. Med. 314 1193.
182. R. Cariou, G. Tobelem, S. Bellucci, J. Soria, C. Soria, J. Maclouf and J. Caen (1988) Effect of lupus anticoagulant on antithrombotic properties of endothelial cells—Inhibition of thrombomodulin-dependent protein C activation. Thromb. Haemost. 60 54.
183. D.A. Taskiris, L. Settas, P.E. Makris and G.A. Marbet (1990) Lupus anticoagulant—antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J. Rheumatol. 17 785.
184. E. Marciniak and E.H. Romond (1989) Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 71 2426.
185. R.G. Malia, S. Kitchen, M. Greaves and F.E. Preston (1990) Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br. J. Haematol. 76 101.
186. M. Ieko, K. Ichikawa, D.A. Triplett, E. Matsuura, T. Atsumi, K. Sawada and T. Koike (1999) Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum. 42 167.
187. T. Atsumi, M.A. Khamashta, O. Amengual and G.R.V. Hughes (1997) Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb. Haemost. 77 222.
188. J.T. Merrill, H.W. Zhang, C. Shen, I.V. Antonov, R.G. Lahita and B.L. Myones (1997) Fluid phase interaction between the anticoagulant protein S and β2-glycoprotein I: Inhibition of protein S capture by immobilized C4b binding protein. Arthritis Rheum. 40 S300.
189. M. Colucci, G. Balconi, R. Lorenzet and P.D. Locati (1983) Cultured human endothelial cells generate tissue factor in response to endotoxin. J. Clin. Invest. 71 1893.
190. J.M. Herbert, P. Savi, M.C. Laplace and A. Lale (1992) IL-4 inhibits LPS-, IL-1 beta- and TNF alpha-induced expression of tissue factor in endothelial cells and monocytes. FEBS Lett. 310 31.
191. Y. Nemerson (1988) Tissue factor and hemostasis. Blood 71 1.
192. L.C. Peterson, S. Valentin and U. Hedner (1995) Regulation of the extrinsic pathway system in health and disease: The role of factor VIIa and tissue factor pathway inhibitor. Thrombo. Res. 79 1.
193. O. Amengual, T. Atsumi, M.A. Khamashta and G.R.V. Hughes (1998) The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb. Haemost. 79 276.
194. D.W. Branch and G.M. Rodgers (1993) Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am. J. Obstet. Gynecol. 168 206.
195. A. Kornberg, M. Blank, S. Kaufman and Y. Shoenfeld (1994) Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J. Immunol. 153 1328.
196. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto and T. Masaki (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 411.
197. E.R. Levin (1995) Endothelins. N. Engl. J. Med. 333 356.
198. S. Nakamura, M. Naruse, K. Naruse, H. Demura and H. Uemura (1990) Immunocytochemical localization of endothelin in cultured bovine endothelial cells. Histochemistry 94 475.
199. T.A. Marsen, M.S. Simonson and M.J. Dunn (1995) Thrombin induces the preproendothelin-1 gene in endothelial cells by a protein tyrosine kinase-linked mechanism. Cir. Res. 76 987.
200. A. Inoue, M. Yanagisawa, Y. Takuwa, Y. Mitsui, M. Kobayashi and T. Masaki (1989) The human preproendothelin-1 gene. J. Biol. Chem. 264 14954.
201. T. Atsumi, M.A. Khamashta, R.S. Haworth, G. Brooks, O. Amengual, K. Ichikawa, T. Koike and G.R.V. Hughes (1998) Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1. Arthritis Rheum. 41 800.
202. S.S. Pierangeli, M. Colden-Stanfield, X. Liu, J.H. Barker, G.L. Anderson and E.N. Harris (1999) Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 99 1997.
203. T. Atsumi, M.A. Khamashta, C. Andujar, M.J. Leandro, O. Amengual, P.R. Ames and G.R.V. Hughes (1998) Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J. Rheumatol. 25 69.
204. M. Yamazaki, H. Asakura, H. Jokaji, M. Saito, C. Uotani, I. Kumabashiri, E. Morishita, K. Aoshima, T. Ikeda and T. Matsuda (1994) Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb. Haemost. 71 424.
205. M. Jurado, J.A. Paramo, M. Gutierrez-Pimentel and E. Rocha (1992) Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb. Haemost. 68 516.
206. T.K. Vu, D.T. Hung, V.I. Wheaton and S.R. Coughlin (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64 1057.
207. A.E. Gharavi, S.S. Pierangeli, M. Colden-Stanfield, X.W. Liu, R.G. Espinola and E.N. Harris (1999) GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J. Immunol. 163 2922.
208. S. Dunoyer-Geindre, E.K. Kruithof, B. Galve-de Rochemonteix, C. Rosnoblet, J. Gruenberg, G. Reber and P. de Moerloose (2001) Localization of β2-glycoprotein 1 in late endosomes of human endothelial cells. Thromb. Haemost. 85 903.
209. J.N. Hawihorne and G.B. Ansell (1982) Phospholipids. Amsterdam: Elsevier Biomedical Press
210. V.A. Fadok, D.R. Voelker, P.A. Campbell, J.J. Cohen, D.L. Bratton and P.M. Henson (1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148 2207.
211. J. Savill, V. Fadok, P. Henson and C. Haslett (1993) Phagocyte recognition of cells undergoing apoptosis. Immunol. Today 14 131.
212. B.E. Price, J. Rauch, M.A. Shia, M.T. Walsh, W. Lieberthal, H.M. Gilligan, T. O'Laughlin, J.S. Koh and J.S. Levine (1996) Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β2-glycoprotein I-dependent manner. J. Immunol. 157 2201.
213. V. Pittoni, C.T. Ravirajan, S. Donohoe, S.J. Machin, P.M. Lydyard and D.A. Isenberg (2000) Human monoclonal anti-phospholipid antibodies selectively bind to membrane phospholipid and β2-glycoprotein I (β2-GPI) on apoptotic cells. Clin. Exp. Immunol. 119 533.
214. M.B. Urowitz, A.A. Bookman, B.E. Koehler, D.A. Gordon, H.A. Smythe and M.A. Ogryzlo (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 60 221.
215. C.J. Homcy, R.R. Liberthson, J.T. Fallon, S. Gross and L.M. Miller (1982) Ischemic heart disease in systemic lupus erythematosus in the young patient: Report of six cases. Am. J. Cardiol. 49 478.
216. R.A. Asherson, N. Harris, A. Gharavi and G.R.V. Hughes (1986) Myocardial infarctio in systemic lupus erythematosus and “lupus-like” disease. Arthritis Rheum. 29 1292.
217. R.A. Asherson, J.K. Chan, E.N. Harris, A.E. Gharavi and G.R. Hughes (1985) Anticardiolipin antibody, recurrent thrombosis and warfarin withdrawal. Ann. Rheum. Dis. 44 823.
218. R. Pauzner, E. Rosner and A. Many (1986) Circulating anticoagulant in systemic lupus erythematosus: Clinical manifestations. Acta Haematol. 76 90.
219. P. Jungers, F. Liote, M.D. Dautzenberg, C. Gazengel, M. Dougados, F. Tron and J.F. Bach (1984) Lupus anticoagulant and thrombosis in systemic lupus erythematosus. Lancet 1 574.
220. N.E. Doherty and R.J. Siegel (1985) Cardiovascular manifestations of systemic lupus erythematosus. Am. Heart J. 110 1257.
221. M.S. Brown and J.L. Goldstein (1994) The hyperlipoproteinemias and other disorders of lipid metabolism. K.D. Isselbacher (Eds) Harrison's Principles of Internal Medicine 13th ed. New York: McGraw-Hill
222. J.L. Witztum and D. Steinberg (1991) Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88 1785.
223. J.L. Goldstein, Y.K. Ho, S.K. Basu and M.S. Brown (1979) Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. U.S.A. 76 333.
224. K.D. O'Brien, C.E. Alpers, J.E. Hokanson, S. Wang and A. Chait (1996) Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation 94 1216.
225. W. Palinski, S. Yla-Herttuala, M.E. Rosenfeld, S.W. Butler, S.A. Socher, S. Parthasarathy, L.K. Curtiss and J.L. Witztum (1990) Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10 325.
226. J.T. Salonen, S. Yla-Herttuala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen, K. Nyyssonen, W. Palinski and J.L. Witztum (1992) Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 883.
227. U.P. Steinbrecher, S. Parthasarathy, D.S. Leake, J.L. Witztum and D. Steinberg (1984) Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. U.S.A. 81 3883.
228. O. Vaarala, G. Alfthan, M. Jauhiainen, M. Leirisalo-Repo, K. Aho and T. Palosuo (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341 923.
229. O. Amengual, T. Atsumi, M.A. Khamashta, F. Tinahones and G.R.V. Hughes (1997) Autoantibodies against oxidised low-density lipoprotein in antiphospholipid syndrome. Br. J. Rheumatol. 36 964.
230. F.J. Tinahones, M.J. Guadrado, M.A. Khamashta, F. Mujic, J.M. Gomez-Zumaquero, E. Collantes and G.R.V. Hughes (1998) Lack of cross-reaction between antibodies to beta2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome. Br. J. Rheumatol. 37 746.
231. F.I. Romero, O. Amengual, T. Atsumi, M.A. Khamashta, F.J. Tinahones and G.R.V. Hughes (1998) Arterial disease in lupus and secondary antiphospholipid syndrome: Association with anti-beta2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br. J. Rheumatol. 37 883.
232. Y. Hasunuma, E. Matsuura, Z. Makita, T. Katahira, S. Nishi and T. Koike (1997) Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol. 107 569.
233. S. Hörkkö, E. Miller, E. Dudl, P. Reaven, L.K. Curtiss, N. Zvaifler, R. Terkeltaub, S. Pierangeli, D.W. Branch, W. Palinski and J.L. Witztum (1996) Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J. Clin. Invest. 98 815.
234. S. Hörkko, E. Miller, D.W. Branch, W. Palinski and J.L. Witztum (1997) The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc. Natl. Acad. Sci. U.S.A. 94 10356.
235. S. Hörkko, D.A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbanagounder, J.A. Berliner, P. Friedman, E.A. Dennis, L.K. Curtiss, W. Palinski and J.L. Witztum (1999) Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103 117.
236. A.D. Watson, N. Leitinger, M. Navab, K.F. Faull, S. Horkko, J.L. Witztum, W. Palinski, D. Schwenke, R.G. Salomon, W. Sha, G. Subbanagounder, A.M. Fogelman and J.A. Berliner (1997) Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272 13597.
237. K. Kobayashi, E. Matsuura, Q. Liu, J. Furukawa, K. Kaihara, J. Inagaki, T. Atsumi, N. Sakairi, T. Yasuda, D.R. Voelker and T. Koike (2001) A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J. Lipid. Res. 42 697.
238. R.L. Griffith, G.T. Virella, H.C. Stevenson and M.F. Lopes-Virella (1988) Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J. Exp. Med. 168 1041.
239. F. Lopes-Virella m.F., N. Binzafar, S. Rackley, A. Takei, M. La Via and G. Virella (1997) The uptake of LDL-IC by human macrophages: Predominant involvement of the Fc gamma RI receptor. Atherosclerosis 135 161.
240. J.C. Khoo, E. Miller, F. Pio, D. Steinberg and J.L. Witztum (1992) Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler. Thromb. 12 1258.
241. P.A. Kiener, B.M. Rankin, P.M. Davis, S.A. Yocum, G.A. Warr and R.I. Grove (1995) Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler. Thromb. Vasc. Biol. 15 990.
242. P.M. Morganelli, R.A. Rogers, T.J. Kitzmiller and A. Bergeron (1995) Enhanced metabolism of LDL aggregates mediated by specific human monocyte IgG Fc receptors. J. Lipid Res. 36 714.
243. J. George, A. Afek, B. Gilburd, M. Blank, Y. Levy, A. Aron-Maor, H. Levkovitz, A. Shaish, I. Goldberg, J. Kopolovic, D. Harats and Y. Shoenfeld (1998) Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I. Circulation 98 1108.
244. J. George, D. Harats, B. Gilburd, A. Afek, Y. Levy, J. Schneiderman, I. Barshack, J. Kopolovic and Y. Shoenfeld (1999) Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: Potential implications for lesion progression. Circulation 99 2227.
245. D.W. Branch, J.R. Scott, N.K. Kochenour and E. Hershgold (1985) Obstetric complications associated with the lupus anticoagulant. N. Engl. J. Med. 313 1322.
246. W.F. Lubbe, W.S. Butler, S.J. Palmer and G.C. Linggins (1984) Lupus anticoagulant in pregnancy. Br. J. Obstet. Gynaecol. 91 357.
247. R. Nayar and J.M. Lage (1994) Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum. Pathol. 27 201.
248. H.J. Out, H.W. Bruinse, G.C. Christiaens, M. van Vliet, J.F. Meilof, P.G. de Groot, R.J. Smeenk and R.H. Derksen (1991) Prevalence of antiphospholipid antibodies in patients with fetal loss. Ann. Rheum. dis. 50 553.
249. C.M. Salafia and A.L. Parke (1997) Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome. Rheum. Dis. Clin. North Am. 23 85.
250. N. di Somone, P.L. Meroni, N. de Papa, E. Raschi, D. Caliandro, C.S. De Carolis, M.A. Khamashta, T. Atsumi, G.R. Hughes, G. Balestrieri, A. Tincani, P. Casali and A. Caruso (2000) Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum. 43 140.